Preferentially Expressed Antigen of Melanoma (PRAME) and Wilmsâ€™ Tumor 1 (WT 1) Genes Expression in Childhood Acute Lymphoblastic Leukemia, Prognostic Role and Correlation with Survival

Engy El Khateeb; Dalia Morgan

doi:10.3889/oamjms.2015.001

Authors

Engy El Khateeb Cairo University Kasr El Aini Faculty of Medicine, Clinical Pathology, Cairo
Dalia Morgan Faculty of Medicine Bany Swef university, Pediatrics Department, Cairo

DOI:

https://doi.org/10.3889/oamjms.2015.001

Keywords:

ALL, PRAME, WT1, RT-PCR, cancer susceptibility, prognosis

Abstract

BACKGROUND: Acute lymphocytic leukemia (ALL) is the most common hematologic malignancy in children. In young children it is also largely curable, with more than 90% of afflicted children achieving long-term remission. PRAME (Preferentially expressed antigen of melanoma) gene belongs to Group 3 class I HLA-restricted widely expressed antigens in which genes encoding widely expressed tumor antigens have been detected in many normal tissues as well as in histologically different types of tumors with no preferential expression on a certain type of cancer. It has been found to be expressed in a variety of cancer cells as leukemia & lymphoma. PRAME monitoring can be useful for detection of minimal residual disease and subsequent relapses particularly those leukemias in which specific tumor markers are unavailable. Wilmsâ€™ tumor1 (WT1) gene was identified as a gene that plays an important role in normal kidney development and inactivation of its function was shown to result in the development of Wilmsâ€™ tumors in paediatric patients. Disruption of WT1 function has been implicated in the formation of many different tumor types.

AIM: to study how PRAME & WT 1 genes expression patterns influence cancer susceptibility & prognosis.

PATIENTS & METHODS: 50 patients with denovo childhood acute lymphoblastic leukemia, as well as 50 age and sex matched apparently healthy volunteers were genotyped for PRAME and WT1 genes expression by reverse transcription polymerase chain reaction (RT-PCR).

RESULTS: PRAME gene was expressed in 34 of the patients (68%) and WT1 gene was expressed in 26 of the patients (52%). Expression of both genes was significantly higher compared to controls (P < 0.0001). Analysis of relapse free survival among our patients revealed that patients expressing PRAME gene or WT1 gene had better relapse free survival (p value=0.02 and 0.01 respectively). Relapse free survival increased significantly among patients coexpressing PRAME and WT 1(p value =0.001)

CONCLUSION: It is concluded that the expression of PRAME and WT1 genes are indicators of favorable prognosis and can be useful tools for monitoring minimal residual disease (MRD) in acute leukemia especially in patients without known genetic markers. Differential expression between acute leukemia patients and healthy volunteers suggests that the immunogenic antigens (PRAME and WT1) are potential candidates for immunotherapy in childhood acute leukemia.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. Lyon (FR): IARC Press, 2004.

Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classiï¬cation and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996; 14:18â€“24. DOI: https://doi.org/10.1200/JCO.1996.14.1.18

Moricke A, Zimmermann M, Reiter A, et al. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr. 2005;217:310â€“320. DOI: https://doi.org/10.1055/s-2005-872515

Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113:1408â€“1411. DOI: https://doi.org/10.1182/blood-2008-06-164863

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde BJ, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. J Immunol. 2007;178(5):2617-21.

Neumann E. Uber myeogene Leukmie. Berl Klin Wochenschr. 1878,15:116.

van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Coulie PG. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells.Br J Haematol. 1998;102(5):1376-9.

Pellat-Deceunynck C, Mellerin MP, LabarriÃ¨re N, Jego G, Moreau-Aubry A, Harousseau JL, Jotereau F, Bataille R. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol. 2000;30(3):803-9. DOI: https://doi.org/10.1002/1521-4141(200003)30:3<803::AID-IMMU803>3.0.CO;2-P

Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4(3):328-32. DOI: https://doi.org/10.1038/nm0398-328

Matsushita M, Ikeda H, Kizaki M, Okamoto S, Ogasawara M, Ikeda Y, Kawakami Y. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol. 2001;112(4):916-26. DOI: https://doi.org/10.1046/j.1365-2141.2001.02670.x

Osaka M, Koami K, Sugiyama T. WT1 contributes to leukemogenesis: expression patterns in 7,12-dimethylbenz[a]anthracene (DMBA)-induced leukemia. Int J Cancer. 1997;72(4):696-9. DOI: https://doi.org/10.1002/(SICI)1097-0215(19970807)72:4<696::AID-IJC23>3.0.CO;2-8

Dietrich et al. Closing the gap for detection of residual posttransplatation leukemia. Blood 2003;101(5):1665-1668. DOI: https://doi.org/10.1182/blood-2002-12-3952

Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, Girotto M, Marinone C, Ferrero D, Gallamini A, Levis A, Saglio G. Piedmont Study Group on Myleodysplastic Syndromes. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol. 2003;21(10):1988-95. DOI: https://doi.org/10.1200/JCO.2003.10.503

Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A, Kim EH, Hosen N, Murakami M, Fujioka T, Masuda T, Taniguchi Y, Nishida S, Oji Y, Oka Y, Sugiyama H. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood. 2003;101(5):1698-704. DOI: https://doi.org/10.1182/blood-2002-06-1831

Fiedler, Disel U, Baslamisili F. One step RT-PCR system. Practical immunology.1997;2:115-120.

Wadelin F, Fulton J, McEwan PA, Spriggs KA, Emsley J, Heery DM. Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol Cancer. 2010;9:226. DOI: https://doi.org/10.1186/1476-4598-9-226

Steinbach D, Viehmann S, Zintl F, Gruhn B. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2002;138:89-91. DOI: https://doi.org/10.1016/S0165-4608(02)00582-4

Greiner J, DÃ¶hner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica. 2006;91(12):1653-61.

Van Baren N, Chambost H, Ferrant A, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells is expressed in acute leukemia cells. Br J Haematol. 1998;102:1376â€“1379. DOI: https://doi.org/10.1046/j.1365-2141.1998.00982.x

Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol. 2005;79(4):257-61. DOI: https://doi.org/10.1002/ajh.20425

Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR, Allen RE, Singer MI, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA. 2005; 102:6092-6097. DOI: https://doi.org/10.1073/pnas.0501564102

Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley T, Yang T, Epping MT, Shou Y, Pogosova-Agadjanyan E, et al. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood. 2009; 114:3299-3308. DOI: https://doi.org/10.1182/blood-2008-07-170282

Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 2006; 103:2794-2799 DOI: https://doi.org/10.1073/pnas.0510423103

Qin Y, Zhu H, Jiang B, Li J, Lu X, Li L, Ruan G, Liu Y, Chen S, Huang X. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res. 2009; 33:384-390. DOI: https://doi.org/10.1016/j.leukres.2008.08.026

Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H, Bullinger L. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 2006, 108:4109-4117. DOI: https://doi.org/10.1182/blood-2006-01-023127

Santamaria C, Chillon MC, Garcia-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Ramos F, Bernal T, Queizan JA, Penarrubia MJ, et al. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. Haematologica. 2008, 93:1797-1805. DOI: https://doi.org/10.3324/haematol.13214

Tajeddine N, Millard I, Gailly P, Gala JL. Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med. 2006; 44:548-555. DOI: https://doi.org/10.1515/CCLM.2006.106

Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O'Driscoll L. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat. 2008; 109:359-365. DOI: https://doi.org/10.1007/s10549-007-9643-3

Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R: PRAME expression and clinical outcome of breast cancer. Br J Cancer. 2008; 99:398-403. DOI: https://doi.org/10.1038/sj.bjc.6604494

Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res. 2004; 10:4307-4313. DOI: https://doi.org/10.1158/1078-0432.CCR-03-0813

Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 2007; 9(14):1â€“17. DOI: https://doi.org/10.1017/S1462399407000336

King-Underwood L, Pritchard-Jones K. Wilmsâ€™ tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood. 1998; 91(8):2961â€“8. DOI: https://doi.org/10.1182/blood.V91.8.2961.2961_2961_2968

Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, et al. Presence of Wilmsâ€™ tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia. 1995; 9(6):1060â€“7.

Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia. 1992;6: 405-9.

Barragan E, Cervera J, Bolufer P, Ballester S, Martin G, Fernandez P et al. Prognostic iplications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica. 2004; 89: 926â€“933.

Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients â€“ results from a single-centre study. Br J Haematol. 2004; 125: 590â€“600. DOI: https://doi.org/10.1111/j.1365-2141.2004.04952.x

Magyarosy E, Varga N, Timar J, Raso E. Follow-up of minimal residual disease in acute childhood lymphoblastic leukemia by WT1 gene expression in the peripheral blood: the Hungarian experience. Pediatr Hematol Oncol. 2003; 20: 65â€“74. DOI: https://doi.org/10.1080/08880010390158568

Trka J, Kalinova M, Hrusak O, Zuna J, Krejci O, Madzo J et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia. 2002; 16: 1381â€“1389. DOI: https://doi.org/10.1038/sj.leu.2402512

Niegemann E, Wehner S, Kornhuber B, Schwabe D, Ebener U. wt1 gene expression in childhood leukemias. Acta Haematol. 1999; 102: 72â€“76. DOI: https://doi.org/10.1159/000040973

Ozgen U, Anak S, Ozbek U, Sarper N, Eryilmaz E, Agaoglu L et al. wt1 gene expression in childhood acute leukemias. Acta Haematol. 2000; 103: 229â€“230. DOI: https://doi.org/10.1159/000041057

Ramirez O, Linares A, Trujillo ML, Caminos JE. WT1 mRNA in cerebrospinal fluid associated with relapse in pediatric lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003; 25: 453â€“458. DOI: https://doi.org/10.1097/00043426-200306000-00006

Garg M, Moore H, Tobal K, Liu Yin JA. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol. 2003; 123: 49â€“59. DOI: https://doi.org/10.1046/j.1365-2141.2003.04552.x

Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O, Browne P, Stary J, McCann SR, Trka J, Lawler M. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia. 2006;20(2):254-63. DOI: https://doi.org/10.1038/sj.leu.2404047

Miglino M, Colombo N, Pica G, Grasso R, Clavio M, Bergamaschi M, Ballerini F, Ghiso A, Ghiggi C, Mitscheunig L, Beltrami G, Cagnetta A, Vignolo L, Lucchetti MV, Aquino S, Pierri I, Sessarego M, Carella AM, Gobbi M. WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma. 2011;52(10):1961-9 DOI: https://doi.org/10.3109/10428194.2011.585673